Prostate imaging scoring systems: indications, interpretation, and clinical impact.

Authors

Emanuele Messina, Antonella Borrelli, Georgios Agrotis, Giorgio Brembilla, Maarten de Rooij, Ludovica Laschena, Francesca Mezzapesa, Ailin Dehghanpour, Francesco Giganti, Ivo G Schoots, Valeria Panebianco

Published in

BJR open. Volume 8. Issue 1. Pages tzag021. Epub Oct 16, 2026.

Abstract

Prostate imaging, and especially multiparametric magnetic resonance imaging (mpMRI), has become central to the diagnosis, risk stratification, treatment planning, and follow-up of prostate cancer. Its widespread adoption has driven the development of structured imaging scoring systems designed to standardize acquisition, interpretation, and reporting across diverse clinical scenarios. This narrative review summarizes the principles, clinical applications, strengths, and limitations of the main prostate imaging scoring systems currently in use. These include PI-RADS for cancer detection, PRECISE for monitoring patients on active surveillance, PI-RR for post-treatment local recurrence, PI-FAB and TARGET for assessment after focal therapy, Node-RADS for lymph node evaluation, MET-RADS-P for whole-body MRI assessment of metastatic disease, PSMA-RADS for molecular imaging interpretation, and PI-QUAL for prostate MRI quality assurance. Collectively, these systems provide a shared diagnostic language that improves inter-reader agreement, supports evidence-based decision-making, and facilitates multidisciplinary care. Despite their proven clinical impact, challenges remain, including inter-reader variability, heterogeneous MRI quality, limited access to advanced imaging, and incomplete validation of emerging tools. Future directions include the incorporation of artificial intelligence, hybrid PET/MRI, and combined clinical-genomic biomarkers, together with prospective multicenter validation, to advance precision, reproducibility, and personalization in prostate cancer imaging.

PMID:
42904263
Bibliographic data and abstract were imported from PubMed on 23 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.